Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SP1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0031960 | Stomach | GC | response to corticosteroid | 30/1159 | 167/18723 | 1.18e-07 | 7.16e-06 | 30 |
GO:0051384 | Stomach | GC | response to glucocorticoid | 27/1159 | 148/18723 | 3.64e-07 | 1.90e-05 | 27 |
GO:00003026 | Stomach | GC | response to reactive oxygen species | 32/1159 | 222/18723 | 6.94e-06 | 2.57e-04 | 32 |
GO:00513486 | Stomach | GC | negative regulation of transferase activity | 36/1159 | 268/18723 | 9.70e-06 | 3.27e-04 | 36 |
GO:00485456 | Stomach | GC | response to steroid hormone | 42/1159 | 339/18723 | 1.40e-05 | 4.54e-04 | 42 |
GO:0030595 | Stomach | GC | leukocyte chemotaxis | 32/1159 | 230/18723 | 1.45e-05 | 4.68e-04 | 32 |
GO:0050900 | Stomach | GC | leukocyte migration | 44/1159 | 369/18723 | 2.30e-05 | 6.81e-04 | 44 |
GO:19016546 | Stomach | GC | response to ketone | 28/1159 | 194/18723 | 2.49e-05 | 7.19e-04 | 28 |
GO:00515916 | Stomach | GC | response to cAMP | 17/1159 | 93/18723 | 5.02e-05 | 1.19e-03 | 17 |
GO:00425426 | Stomach | GC | response to hydrogen peroxide | 22/1159 | 146/18723 | 9.34e-05 | 1.92e-03 | 22 |
GO:0097529 | Stomach | GC | myeloid leukocyte migration | 29/1159 | 220/18723 | 9.69e-05 | 1.97e-03 | 29 |
GO:0002685 | Stomach | GC | regulation of leukocyte migration | 28/1159 | 210/18723 | 1.04e-04 | 2.05e-03 | 28 |
GO:0002683 | Stomach | GC | negative regulation of immune system process | 47/1159 | 434/18723 | 1.36e-04 | 2.52e-03 | 47 |
GO:00328724 | Stomach | GC | regulation of stress-activated MAPK cascade | 26/1159 | 192/18723 | 1.40e-04 | 2.59e-03 | 26 |
GO:00466836 | Stomach | GC | response to organophosphorus | 20/1159 | 131/18723 | 1.59e-04 | 2.84e-03 | 20 |
GO:00703024 | Stomach | GC | regulation of stress-activated protein kinase signaling cascade | 26/1159 | 195/18723 | 1.81e-04 | 3.13e-03 | 26 |
GO:00064696 | Stomach | GC | negative regulation of protein kinase activity | 27/1159 | 212/18723 | 2.93e-04 | 4.70e-03 | 27 |
GO:00310985 | Stomach | GC | stress-activated protein kinase signaling cascade | 30/1159 | 247/18723 | 3.20e-04 | 5.10e-03 | 30 |
GO:00459366 | Stomach | GC | negative regulation of phosphate metabolic process | 46/1159 | 441/18723 | 3.71e-04 | 5.73e-03 | 46 |
GO:00105636 | Stomach | GC | negative regulation of phosphorus metabolic process | 46/1159 | 442/18723 | 3.90e-04 | 5.97e-03 | 46 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05016210 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
hsa05415211 | Esophagus | ESCC | Diabetic cardiomyopathy | 146/4205 | 203/8465 | 5.81e-11 | 7.78e-10 | 3.99e-10 | 146 |
hsa05163210 | Esophagus | ESCC | Human cytomegalovirus infection | 148/4205 | 225/8465 | 5.73e-07 | 4.00e-06 | 2.05e-06 | 148 |
hsa04137210 | Esophagus | ESCC | Mitophagy - animal | 54/4205 | 72/8465 | 9.33e-06 | 4.96e-05 | 2.54e-05 | 54 |
hsa0501728 | Esophagus | ESCC | Spinocerebellar ataxia | 94/4205 | 143/8465 | 6.77e-05 | 2.90e-04 | 1.48e-04 | 94 |
hsa043507 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa015227 | Esophagus | ESCC | Endocrine resistance | 63/4205 | 98/8465 | 2.38e-03 | 6.58e-03 | 3.37e-03 | 63 |
hsa0492816 | Esophagus | ESCC | Parathyroid hormone synthesis, secretion and action | 66/4205 | 106/8465 | 5.86e-03 | 1.47e-02 | 7.51e-03 | 66 |
hsa052319 | Esophagus | ESCC | Choline metabolism in cancer | 61/4205 | 98/8465 | 7.97e-03 | 1.92e-02 | 9.84e-03 | 61 |
hsa0501638 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
hsa0541538 | Esophagus | ESCC | Diabetic cardiomyopathy | 146/4205 | 203/8465 | 5.81e-11 | 7.78e-10 | 3.99e-10 | 146 |
hsa0516338 | Esophagus | ESCC | Human cytomegalovirus infection | 148/4205 | 225/8465 | 5.73e-07 | 4.00e-06 | 2.05e-06 | 148 |
hsa0413738 | Esophagus | ESCC | Mitophagy - animal | 54/4205 | 72/8465 | 9.33e-06 | 4.96e-05 | 2.54e-05 | 54 |
hsa0501736 | Esophagus | ESCC | Spinocerebellar ataxia | 94/4205 | 143/8465 | 6.77e-05 | 2.90e-04 | 1.48e-04 | 94 |
hsa0435014 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0520213 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa0152215 | Esophagus | ESCC | Endocrine resistance | 63/4205 | 98/8465 | 2.38e-03 | 6.58e-03 | 3.37e-03 | 63 |
hsa0492817 | Esophagus | ESCC | Parathyroid hormone synthesis, secretion and action | 66/4205 | 106/8465 | 5.86e-03 | 1.47e-02 | 7.51e-03 | 66 |
hsa0523114 | Esophagus | ESCC | Choline metabolism in cancer | 61/4205 | 98/8465 | 7.97e-03 | 1.92e-02 | 9.84e-03 | 61 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SP1 | SNV | Missense_Mutation | rs775622089 | c.314A>G | p.Asn105Ser | p.N105S | P08047 | protein_coding | deleterious(0.01) | probably_damaging(0.968) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SP1 | SNV | Missense_Mutation | | c.49N>T | p.Ile17Phe | p.I17F | P08047 | protein_coding | tolerated_low_confidence(0.08) | benign(0.227) | TCGA-AN-A0FJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SP1 | SNV | Missense_Mutation | | c.1262N>T | p.Ser421Leu | p.S421L | P08047 | protein_coding | deleterious(0.01) | possibly_damaging(0.587) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SP1 | SNV | Missense_Mutation | | c.1997N>A | p.Arg666His | p.R666H | P08047 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SP1 | SNV | Missense_Mutation | | c.202T>C | p.Cys68Arg | p.C68R | P08047 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
SP1 | SNV | Missense_Mutation | novel | c.407N>G | p.Ser136Cys | p.S136C | P08047 | protein_coding | deleterious(0.01) | possibly_damaging(0.648) | TCGA-GM-A3XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
SP1 | insertion | Nonsense_Mutation | novel | c.1611_1612insCCAGTTTTATTTTGATTGTTTTCTTTGGAA | p.Leu537_Gly538insProValLeuPheTerLeuPheSerLeuGlu | p.L537_G538insPVLF*LFSLE | P08047 | protein_coding | | | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SP1 | SNV | Missense_Mutation | | c.2022N>C | p.Gln674His | p.Q674H | P08047 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
SP1 | SNV | Missense_Mutation | | c.2022N>C | p.Gln674His | p.Q674H | P08047 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
SP1 | SNV | Missense_Mutation | novel | c.2009N>T | p.Ser670Leu | p.S670L | P08047 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |